Virtual Library
Start Your Search
M. Krasnik
Moderator of
-
+
SH03 - WCLC 2016 Scientific Highlights - Surgery and Early Stage NSCLC I - III (ID 485)
- Event: WCLC 2016
- Type: Scientific Highlights
- Track: Early Stage NSCLC
- Presentations: 3
- Moderators:W. Klepetko, M. Krasnik
- Coordinates: 12/06/2016, 07:30 - 08:30, Hall C1
-
+
SH03.01 - Surgery (ID 7123)
07:30 - 07:50 | Author(s): S. Cicenas
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
SH03.02 - NSCLC Stage I-II (ID 7124)
07:50 - 08:10 | Author(s): E. Fadel
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
SH03.03 - NSCLC Stage III (ID 7125)
08:10 - 08:30 | Author(s): V. Westeel
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
Author of
-
+
OA07 - Lymph Node Metastases and Other Prognostic Factors for Local Spread (ID 376)
- Event: WCLC 2016
- Type: Oral Session
- Track: Surgery
- Presentations: 1
-
+
OA07.07 - Discussant for OA07.05, OA07.06, OA07.07 (ID 7074)
15:25 - 15:40 | Author(s): M. Krasnik
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P1.06 - Poster Session with Presenters Present (ID 458)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.06-042 - The Importance of Medication Related Osteonecrosis of the Jaws (MRONJ) (ID 4309)
14:30 - 14:30 | Author(s): M. Krasnik
- Abstract
Background:
Medication related osteonecrosis of the jaws (MRONJ) is an increasing problem globally, which may lead to loss of teeth and jaw bone and has a significant impact on qualtity of life. MRONJ is known since 2003, reported after antiresorptive treatment with bisphosphonate, and since 2010 also from Denosumab for skeletal metastases from breast cancer, prostate cancer and multiple myeloma, Recently, MRONJ has also been related to chemotherapy, including Tyrosine Kinase Inhibitors for lung cancer, kidney cancer and gastrointestinal cancer without skeletal metastases. The onset of MRONJ is often precipitated by of one of the above medication types in combination with a tooth extraction. Therefore it is recommended that all patients have a dental screening and relevant dental treatment before the start of medication with antiresorptives (bisphosphobnates/denosumab) or Tyrosine Kinase Inhibitors The purpose of this pstudy is to raise awareness that MRONJ can be prevented and that MRONJ also occurs among patients receiving chemotherapy without bisphosphonates or denosumab. .
Methods:
Rigshospitalet established the Copenhagen ONJ Cohort of consecutive patients with MRONJ since 2004, and have performed systematic prospective data collection since 2010.
Results:
Among 247 patients enrolled in the Copenhagen ONJ Cohort 163 had cancer and received treatment with bishosphonates in 109 cases and denosumab in 54 cases. In addition, since 2013 we have received 7 patients with MRONJ from Tyrosine Kinase inhibitors. In 85 out of 163 cancer patients (52%) the onset of MRONJ was related to tooth extraction.
Conclusion:
More than 50% of the MRONJ cases could potentially be avoided.If all patients had dental examination and had repaired or extracted bad teeth before start of antiresorptive medication, Thus all cancer patients should have dental examination before start of medical treatment.
